This report provides top-line data relating to the clinical trials on cystic fibrosis. This report includes an overview of trials count and their average enrollment in top countries conducted globally. It also includes coverage of disease clinical trials by region and top countries, trial phase, trial status, end points status, and sponsor type. Moreover, the report provides prominent drug names and trial counts for in-progress trials (based on the number of ongoing trials).

The cystic fibrosis clinical trial report consists of 1164 trials conducted by companies in Phase IV, Phase III, Phase II, and Phase I. Out of 823 completed trials, over 400 trials have achieved end points. The number of cystic fibrosis clinical trials conducted globally has decreased by 30% for the period 2016-2020. The average number of patients enrolled was highest in the year 2020. More than 50% of the trials have been sponsored by companies and over 40% by institutions.

What are the top regions and countries in the cystic fibrosis clinical trials market?

In total there were 1,164 clinical trials conducted on cystic fibrosis. Out of them, more than 35% were conducted in Europe and North America. It was followed by Asia-Pacific with more than 10%, the Middle East and Africa at about 5% each, and the lowest was South and Central America. The UK had the highest number of cystic fibrosis clinical trials among the European countries, accounting for nearly 30% of the clinical trials in the region. The US had the highest number of cystic fibrosis clinical trials in North America and Australia had the highest number of cystic fibrosis clinical trials in the Asia-Pacific region. Israel had the highest number of cystic fibrosis clinical trials in the Middle East and Africa and Argentina had the highest number of cystic fibrosis clinical trials in South and Central America.

In the country-wise analysis, the US had the highest number of cystic fibrosis clinical trials as well as the highest number of trials in progress. The US is followed by the UK and Germany in the highest number of trials. Spain had the highest average patient enrollment in cystic fibrosis clinical trials. Other top countries include Canada, Australia, Belgium, France, Italy, and the Netherlands.

Cystic fibrosis clinical trials market in G7 countries

Among the G7 (the US, the UK, Germany, France, Italy, Canada, and Japan) countries, there were 1,107 clinical trials conducted as of December 2021. Of these, the US had the highest number of clinical trials. France has the highest proportion of cystic fibrosis to respiratory clinical trials as of December 2021.

Cystic fibrosis clinical trials market in E7 countries:

As of December 2021, among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, there were a total of 61 clinical trials being conducted. Of these, Russia had the highest number of clinical trials as well as the highest proportion of cystic fibrosis to respiratory clinical trials.

Cystic fibrosis clinical trials market, by region

For more regional insights, download a free report sample

What are the phases in the cystic fibrosis clinical trials market?

As of December 2021, there were 414 clinical trials in Phase II, of which over 40 clinical trials were in progress for the time period of 1995-2021. Phase II had the maximum number of clinical trials in progress accounting for more than 30% of the trials.

Which are the key sponsors in the cystic fibrosis clinical trials market?

The key sponsors in the cystic fibrosis clinical trials market are Vertex Pharmaceuticals Inc, Cystic Fibrosis Foundation, Novartis AG, Gilead Sciences Inc, C. H. Boehringer Sohn AG & Co KG, Galapagos NV, F. Hoffmann-La Roche Ltd, AbbVie Inc, Merck & Co Inc, and Yumanity Therapeutics Inc. Among them, Vertex Pharmaceuticals Inc has conducted the highest number of cystic fibrosis clinical trials.

Cystic fibrosis clinical trials market, by key sponsors

To know more about key sponsors, download a free report sample

Market report scope

The report provides an in-depth analysis of:

• Top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and end point status.
• Top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company.
• All the unaccomplished trials (terminated, suspended, and withdrawn) with the reason for unaccomplishment.
• Enrollment trends for the past five years.
• Latest news for the past three months.

Reasons to Buy

• Assists in formulating key business strategies with regard to investment.
• Helps in identifying prominent locations for conducting clinical trials which saves time and cost
• Provides top-level analysis of the global clinical trials market which helps in identifying key business opportunities.
• Supports understanding of trials count and enrollment trends by country in the global therapeutics market.
• Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials.
• Facilitates clinical trial assessment of the indication on a global, regional, and country-level.